ZUG, Switzerland, SAN JUAN, Puerto Rico and TORONTO, November 25, 2024 – Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment of obesity and associated metabolic diseases, today announced that Steffen-Sebastian Bolz, MD, Ph.D., Chief Scientific Officer of Aphaia Pharma, will participate in a panel discussion at the 1st Annual Obesity & Metabolic Innovation Forum, taking place December 4, 2024, in Boston, Massachusetts. The panel will provide unique perspectives on the rapid growth of GLP-1 drugs and their potential to address the root causes of chronic diseases, such as obesity.
Details on the presentation are as follows:
Panel: The Future of GLP-1 Drugs – A Panacea for Chronic Disease?
Date: Wednesday, December 4, 2024, at 3:30 p.m. EST
Location: Convene One Boston Place
Aphaia Investor Contact
Günter Jucho
Chief Financial Officer
jucho@aphaiapharma.com
43rd Annual J. P. Morgan Health Conference in San Francisco
From 10 - 16 January, Günter Jucho, CFO of Aphaia Pharma AG,…
